80.14 0.00 (0.00%)
After hours: 6:19PM EST
|Bid||80.15 x 1200|
|Ask||80.24 x 800|
|Day's range||79.67 - 80.89|
|52-week range||65.25 - 92.64|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||17.70|
|Forward dividend & yield||2.60 (3.24%)|
|Ex-dividend date||14 Dec 2020|
|1y target est||N/A|
Let's see if Merck & Co (MRK) stock is a good choice for value-oriented investors right now from multiple angles.
The acquisition of OncoImmune will boost Merck's (MRK) portfolio with CD24Fc, a candidate in phase III studies for the treatment of patients with severe and critical COVID-19.
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...